The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.25
Bid: 17.50
Ask: 19.00
Change: 0.00 (0.00%)
Spread: 1.50 (8.571%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 18.00
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Increased investment in THWLC

3 Jan 2017 07:00

RNS Number : 1138T
OptiBiotix Health PLC
03 January 2017
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Increased investment in The Healthy Weight Loss Company Ltd

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces an increase in its investment in its majority owned subsidiary The Health Weight Loss Company Limited ("THWLC").

 

Under the terms of the agreement OptiBiotix has made an investment of £75,000 to provide working capital to support marketing and an increase in stock levels. This investment increases OptiBiotix's shareholding in THWLC to 64%.

 

OptiBiotix announced on 26 July 2016 that it had acquired a majority shareholding in THWLC to incubate new technological solutions and develop wider product applications in weight management. THWLC produces GoFigure® products containing SlimBiome® which incorporates OptiBiotix's patented combination of natural ingredients developed by experts to support weight loss (see www.GoFigureDiet.com). Since investment:-

 

· THWLC has gained over 1,000 customers, retail listings in over 80 stores, and 4 distributorships in the UK and Iceland

· Sales have outperformed expectations with GoFigure® products receiving excellent customer reviews on Amazon and customer surveys reporting average weight loss of 2 ½lbs per week

· GoFigure® was voted finalist in "Best New Health & Nutrition" at the 2016 European Natural & Organic Awards

· As announced on 13 December 2016 GoFigure® products have attracted corporate interest leading to an agreement with a major multinational to develop food and Over The Counter ("OTC") products containing OptiBiotix's SlimBiome® technology for the Asian market,

 

This increased investment will provide THWLC with the resources to build on its early success to:-

1. Invest in product marketing at key seasonal periods

2. Provide the marketing support required for listing in major retail outlets

3. Increase the number of retail listings, particularly with major retail outlets, selling GoFigure® products both within the UK and internationally

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are really pleased with the progress of THWLC and the rapid sales growth of its GoFigure® products which have shown the unique ability of our SlimBiome® technology to help customers lose weight without feeling hungry, leading to easier and more successful dieting. Our belief in the potential of THWLC is demonstrated by this additional investment which provides funds to invest in marketing, to build stock levels to meet the seasonal demand for weight management products, and to support an increase in retail listings, particularly with major retail outlets. I am sure investors will recognise that given the early success of GoFigure® products, which has been achieved without any marketing, there is potential for strong sales growth of GoFigure® products over the next few years and substantial value enhancement."

 

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

Cairn Financial Advisers LLP

Tel: 020 7213 0883

Liam Murray

 

finnCap Broker

 

Tel: 020 7220 0500

Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)

Tony Quirke (Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

Mike Wort

Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

About The Healthy Weight Loss Company

The Healthy Weight Loss Company (THWLC) is jointly owned by OptiBiotix Health plc (64%), Anna Maia, and Max Tomlinson. The Company was formed in July 2016 as a platform for OptiBiotix to incubate new technological solutions and develop wider product applications in weight management.

 

The technology incubator was created to provide an effective way to substantiate the commercial viability of early product concepts. THWLC sells GoFigure® snacks and shakes containing OptiBiotix's proprietary Slimbiome® technology under a non-exclusive UK license agreement. www.GoFigureDiet.com. The use of SlimBiome® in the GoFigure® range establishes use of the technology in food products and supports the wider use of Slimbiome® technology in dietary supplements and over the counter (OTC) applications, both in the UK and internationally.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBRBDDBBXBGLG
Date   Source Headline
30th Apr 20247:00 amRNSManufacturing agreement with KAG Industries
15th Apr 20248:49 amRNSHolding(s) in Company
25th Mar 20247:00 amRNSPlacing, Subscription and Director Dealing
18th Mar 202411:36 amRNSHolding(s) in Company
13th Mar 20247:00 amRNSPartnership agreement with Morepen for SlimBiome
8th Mar 20244:09 pmRNSHolding(s) in Company
27th Feb 20247:00 amRNSStrategic and commercial update
9th Feb 20247:00 amRNSChange of auditor
5th Feb 20247:00 amRNSPresentation at ProBiota 2024
30th Jan 20247:00 amRNSSweetBiotix Update
15th Jan 20247:00 amRNSLaunch of LeanBiome in Muscletech
4th Dec 20237:00 amRNSDirectorate Change
28th Nov 20237:00 amRNSDistribution agreement for SlimBiome
24th Nov 20237:00 amRNSHolding(s) in Company
22nd Nov 20237:00 amRNSBBSRC Grant for WellBiome®
1st Nov 20237:00 amRNSCommercial update
23rd Oct 20237:00 amRNSLicense agreement with Tata Chemicals
19th Oct 20233:02 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSHalf-year Report
22nd Sep 20237:00 amRNSPlanned launch of OptiBiotix products with Boots
29th Aug 20237:00 amRNSCommercial update
31st Jul 202312:51 pmRNSHolding(s) in Company
26th Jul 202312:34 pmRNSResult of AGM
19th Jul 20237:00 amRNSSweetBiotix® overview
28th Jun 20237:00 amRNSFinal Results
4th May 20237:00 amRNSInvestor update
21st Mar 20237:00 amRNSChange of Broker
15th Mar 20237:00 amRNSSlimbiome study results
21st Feb 20237:00 amRNSDirectorate Change
30th Jan 20234:28 pmRNSHolding(s) in Company
5th Dec 20227:00 amRNSIssue of Equity – Subscription
10th Nov 202211:30 amRNSInvestor update
1st Nov 20227:00 amRNSLaunch of GoFigure products on Tmall China
24th Oct 20227:00 amRNSApproval of GoFigure products
17th Oct 20227:00 amRNSNew health claims for SlimBiome in Australia
17th Oct 20227:00 amRNSNew health claims for SlimBiome in Australia
28th Sep 20227:00 amRNSHalf-year Report
26th Sep 20227:00 amRNSLaunch of novel prebiotic in Europe and Africa
20th Sep 20227:00 amRNSLaunch of GoFigure range with Apollo Hospitals
14th Sep 20227:00 amRNSNew commercialisation partner in Asia Pacific
24th Aug 20224:41 pmRNSSecond Price Monitoring Extn
24th Aug 20224:35 pmRNSPrice Monitoring Extension
24th Aug 20222:06 pmRNSSecond Price Monitoring Extn
24th Aug 20222:00 pmRNSPrice Monitoring Extension
24th Aug 202211:06 amRNSSecond Price Monitoring Extn
24th Aug 202211:00 amRNSPrice Monitoring Extension
24th Aug 20229:05 amRNSSecond Price Monitoring Extn
24th Aug 20229:00 amRNSPrice Monitoring Extension
24th Aug 20227:00 amRNSTrading update
26th Jul 202212:31 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.